TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01473979

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical closure of the poststernotomy wound infection
Description: Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical closure of the poststernotomy wound infection
Description: Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone.
Study: NCT04530773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watch VR movies/ Play VR games
Description: The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watch VR movies/ Play VR games
Description: The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watch VR movies/ Play VR games
Description: The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watch VR movies/ Play VR games
Description: The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watch VR movies/ Play VR games
Description: The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.
Study: NCT00997451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-management
Description: Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom monitoring
Description: Daily symptom via web diary
Study: NCT04497116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500 (camonsertib)
Description: Oral ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500 (camonsertib)
Description: Oral ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500 (camonsertib)
Description: Oral ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Oral PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: Gemcitabine
Study: NCT01059110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salicylate ointment
Description: cream, one application every night, for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-Uracil
Description: cream, one application every night, during 12 hours, for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 2 cycles of 5 seconds after obtention of halo of white
Study: NCT02580942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic stickers
Description: 36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham magnetic stickers
Description: 36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Description: 72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Chinese herbal medicine
Description: 72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
Study: NCT03951051

Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan Medoxomil 40 mg
Description: Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.

Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan Medoxomil 40 mg
Description: Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.

Intervention type: DRUG
Group type: OTHER
Intervention: Olmetec®
Description: Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.

Intervention type: DRUG
Group type: OTHER
Intervention: Olmetec®
Description: Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
Study: NCT01391403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisinin
Description: 400 mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg/day
Study: NCT02933099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant+palonosetron+dexamethasone
Description: Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron+dexamethasone
Description: Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
Study: NCT00151983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
Study: NCT01936636

Intervention type: DRUG
Intervention: Fentanyl
Study: NCT03456648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: non-vitamin K oral anticoagulant (NOAC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: non-vitamin K oral anticoagulant (NOAC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: non-vitamin K oral anticoagulant (NOAC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: non-vitamin K oral anticoagulant (NOAC)
Study: NCT04305275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-324
Description: SAGE-324 oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-324 Placebo
Description: SAGE-324 matched placebo oral tablet
Study: NCT03275571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cCBT intervention
Description: During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
Study: NCT01269762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LipoCol Forte
Description: Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
Study: NCT02528370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telEPOC
Description: The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
Study: NCT04267770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (circadian)
Description: Participant's own insulin adjusted to circadian infusion rates

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (flat rate)
Description: Participant's own insulin set to flat basal rates
Study: NCT00489814

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
Study: NCT04037748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puran T4®
Description: Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puran T4®
Description: Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutirox®
Description: Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutirox®
Description: Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
Study: NCT04006496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing Coaching
Description: For the intervention group, a trained expressive writing expert/coach will introduce the expressive writing concept to consented patients during the first visit, followed by an introduction of the first expressive writing exercise and prompt. The expert/coach will introduce new writing prompts at each subsequent visit. A script containing each visit's writing prompt and instructions will also be left with the patients for future use and/or reference. The trained clinician will collect, read, and analyze the writing sample using a health coaching technique by: 1) summarizing what the patient wrote, 2) evoking double-sided reflection by reading back the writing sample to the patient, and 3) developing a metaphor and review with the patient. Patients will also have the opportunity to ask the trained clinician questions and receive guidance.
Study: NCT02951286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high pull headgear + OBA
Description: a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBA (control group)
Description: A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
Study: NCT03061175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive web-based CPM-DA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02301663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip
Description: Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip
Description: Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip
Description: Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude simulation
Description: Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude simulation
Description: Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude simulation
Description: Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg exercise
Description: Subjects will perform leg exercise to increase metabolic demand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg exercise
Description: Subjects will perform leg exercise to increase metabolic demand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg exercise
Description: Subjects will perform leg exercise to increase metabolic demand.
Study: NCT02613845

Intervention type: OTHER
Intervention: no intervention
Study: NCT03271398

Intervention type: BEHAVIORAL
Intervention: EMDR
Description: Eye movement desensitization and reprocessing (intensive format)

Intervention type: BEHAVIORAL
Intervention: EMDR
Description: Eye movement desensitization and reprocessing (intensive format)

Intervention type: BEHAVIORAL
Intervention: EMDR
Description: Eye movement desensitization and reprocessing (intensive format)

Intervention type: BEHAVIORAL
Intervention: EMDR
Description: Eye movement desensitization and reprocessing (intensive format)

Intervention type: BEHAVIORAL
Intervention: EMDR
Description: Eye movement desensitization and reprocessing (intensive format)

Intervention type: BEHAVIORAL
Intervention: EMDR
Description: Eye movement desensitization and reprocessing (intensive format)

Intervention type: BEHAVIORAL
Intervention: PC
Description: Progressive counting (intensive format)

Intervention type: BEHAVIORAL
Intervention: PC
Description: Progressive counting (intensive format)

Intervention type: BEHAVIORAL
Intervention: PC
Description: Progressive counting (intensive format)

Intervention type: BEHAVIORAL
Intervention: PC
Description: Progressive counting (intensive format)

Intervention type: BEHAVIORAL
Intervention: PC
Description: Progressive counting (intensive format)

Intervention type: BEHAVIORAL
Intervention: PC
Description: Progressive counting (intensive format)
Study: NCT04998838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)
Description: Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Myanmar treatment
Description: Treated according to normal Myanmar processes for HBV positive patients
Study: NCT04341220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation is a noninvasive technique of neuronal modulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation is a noninvasive technique of neuronal modulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercises
Description: Specific balance exercises, focused on balance, postural control and control of the center of gravity within the support base.
Study: NCT00826202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: 60 mg/kg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert Placebo
Study: NCT00256997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (LAI)
Description: Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral atypical Antipsychotic
Description: Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
Study: NCT04341220

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Balance exercises
Description: Specific balance exercises, focused on balance, postural control and control of the center of gravity within the support base.
Study: NCT01866384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mild induced hypothermia
Description: Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Temperature
Description: In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
Study: NCT03451084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN003
Description: Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN003
Description: Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN003
Description: Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN003
Description: Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN003
Description: Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN003
Description: Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
Study: NCT00836043

Intervention type: DRUG
Intervention: Alemtuzumab (MabCampath)
Description: Intravenous therapy according to product information.
Study: NCT02369107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verum acupuncture and medicine
Description: Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture and medicine
Description: Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
Study: NCT03221738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-Based Cognitive Behavioral Therapy
Description: 12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.